Preparation, Physicochemical Characterization and Anti-Fungal Evaluation of Amphotericin B-Loaded PLGA-PEG-Galactosamine Nanoparticles. 2021

Ghobad Mohammadi, and Mostafa Fathian-Kolahkaj, and Pardis Mohammadi, and Khosro Adibkia, and Ali Fattahi
Pharmaceutical Sciences Research Center Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.

The present study aimed to formulate PLGA and PLGA-PEG-galactosamine nanoparticles (NPs) loaded with amphotericin B with appropriate physicochemical properties and antifungal activity. PLGA was functionalized with GalN to increase the adhesion and antifungal activity of NPs against Candida albicans. The physicochemical properties of NPs were characterized by particle size determination, zeta potential, drug crystallinity, loading efficiency, dissolution studies, differential scanning calorimeter (DSC), X-ray powder diffraction (XRPD), and Fourier transform infrared (FT-IR). Antifungal activity of the NPs at different drug/polymer ratios was examined by determining minimum inhibitory concentrations (MICs). the FT-IR and 1 HNMR analysis successfully confirmed the formation of PLGA- PEG-GalN NPs. The PLGA NPs were in the size range of 174.1 ± 3.49 to 238.2±7.59 nm while PLGA-GalN NPs were 255.6 ±4.08 nm in size , respectively. Loading efficiency was in the range of 67%±2.4 to 77%±1.6, and entrapment efficiency in the range of 68.185%±1.9 to 73.05%±0.6. Zeta potential and loading efficiency for PLGA-GalN NPs were -0.456, 71%. The NPs indicated an amorphous status according to XRPD patterns and DSC thermograms. The PLGA-PEG-GalN NPs showed higher fungistatic activity than PLGA NPs. the results demonstrated that the antifungal activity of PLGA-PEG-GalN NPs was higher than pure amphotericin B and PLGA NPs.

UI MeSH Term Description Entries

Related Publications

Ghobad Mohammadi, and Mostafa Fathian-Kolahkaj, and Pardis Mohammadi, and Khosro Adibkia, and Ali Fattahi
February 2017, Pharmaceutical research,
Ghobad Mohammadi, and Mostafa Fathian-Kolahkaj, and Pardis Mohammadi, and Khosro Adibkia, and Ali Fattahi
December 2009, Pharmaceutical research,
Ghobad Mohammadi, and Mostafa Fathian-Kolahkaj, and Pardis Mohammadi, and Khosro Adibkia, and Ali Fattahi
October 2002, Journal of controlled release : official journal of the Controlled Release Society,
Ghobad Mohammadi, and Mostafa Fathian-Kolahkaj, and Pardis Mohammadi, and Khosro Adibkia, and Ali Fattahi
August 2022, Pharmaceutics,
Ghobad Mohammadi, and Mostafa Fathian-Kolahkaj, and Pardis Mohammadi, and Khosro Adibkia, and Ali Fattahi
November 2018, Pharmaceutics,
Ghobad Mohammadi, and Mostafa Fathian-Kolahkaj, and Pardis Mohammadi, and Khosro Adibkia, and Ali Fattahi
February 2005, Journal of microencapsulation,
Ghobad Mohammadi, and Mostafa Fathian-Kolahkaj, and Pardis Mohammadi, and Khosro Adibkia, and Ali Fattahi
December 2017, Journal de mycologie medicale,
Ghobad Mohammadi, and Mostafa Fathian-Kolahkaj, and Pardis Mohammadi, and Khosro Adibkia, and Ali Fattahi
December 2010, Colloids and surfaces. B, Biointerfaces,
Ghobad Mohammadi, and Mostafa Fathian-Kolahkaj, and Pardis Mohammadi, and Khosro Adibkia, and Ali Fattahi
July 2018, Materials (Basel, Switzerland),
Ghobad Mohammadi, and Mostafa Fathian-Kolahkaj, and Pardis Mohammadi, and Khosro Adibkia, and Ali Fattahi
September 2009, International journal of pharmaceutics,
Copied contents to your clipboard!